GleamWall
中文EN

SNDX Syndax Pharmaceuticals Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1395937 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY159.7%
TTM net income YoY32.8%
TTM EPS YoY34.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-61.7%
Net margin-72.3%
FCF margin—
EBITDA margin-55.5%

Returns

ROE-426.4%
ROA-33.7%
ROIC (approx.)—
Asset turnover0.47x

Leverage & solvency

Liabilities / assets102.5%
Debt / equity—
Current ratio4.69x
Interest coverage-44,660.00x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$83.30M$72.79M$64.86M$68.73M$45.87M$37.96M$20.04M$7.68M
R&D expense$67.48M$68.04M$58.84M$78.64M$56.28M$62.23M$61.64M$65.53M
SG&A expense$43.72M$41.54M$37.59M$49.93M$44.92M$43.80M$41.03M$37.69M
Operating income-$41.90M-$39.99M-$34.20M-$62.55M-$57.43M-$69.35M-$83.76M-$96.36M
Interest expense$2,000$2,000$0$0$0$4,000$2,000$4.81M
Income tax$0$0$0$433,000$0$0$0—
Net income-$49.43M-$49.36M-$42.67M-$68.01M-$60.72M-$71.85M-$84.85M-$94.17M
EBITDA-$35.90M-$34.99M-$30.20M-$59.55M-$54.43M-$69.35M-$83.76M—
EPS (basic)-0.55-0.55-0.48—-0.70-0.83-0.98—
EPS (diluted)-0.55-0.55-0.48—-0.70-0.83-0.98—
Weighted avg. shares (diluted)89.79M88.99M88.26M—86.62M86.34M86.17M—
Balance sheet
Cash & equivalents$135.94M$336.48M$130.89M$134.93M$116.81M$108.64M$153.99M$154.08M
Short-term investments$291.16M$211.38M$221.17M$259.14M$319.17M$346.60M$358.20M$418.80M
Receivables———$38.00M———$7.60M
Inventory$39.38M$33.16M$34.95M$32.75M$25.00M$17.70M$4.66M$366,000
Current assets$567.44M$675.04M$471.18M$528.08M$529.83M$531.68M$548.75M$603.06M
PP&E, net$206,000$212,000$177,000$181,000$128,000$0$0$0
Total assets$692.67M$703.65M$472.67M$529.71M$551.79M$596.15M$640.71M$724.82M
Current liabilities$120.96M$99.68M$86.17M$120.12M$114.19M$112.99M$94.55M$103.55M
Short-term debt$344.10M$344.03M$343.96M$343.91M$343.91M$343.85M$343.79M$343.68M
Total liabilities$709.85M$688.55M$431.05M$465.08M$436.36M$438.73M$425.65M$436.69M
Shareholders' equity-$17.18M$15.10M$41.62M$64.63M$115.43M$157.42M$215.06M$288.12M
Shares outstanding89.99M89.15M88.54M87.41M86.91M86.06M86.05M85.69M
Cash flow statement
Operating cash flow-$27.25M-$30.27M-$50.34M-$69.49M-$70.53M-$87.80M-$95.16M-$57.39M
Investing cash flow-$176.47M-$16.91M$38.39M$81.58M$72.43M$41.89M$94.14M-$268.97M
Financing cash flow$3.19M$252.77M$7.92M$5.92M$6.28M$551,000$930,000$347.43M
Depreciation & amortization$6.00M$5.00M$4.00M$3.00M$3.00M$0$0—
Stock-based compensation$15.29M$14.01M$12.05M$11.25M$12.08M$13.79M$10.38M$12.30M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.